Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 7/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.36 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 2/20 | 0.35 |
| ▸ | OGA | O60502 | 1/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.34 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.34 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | PDE8B | O95263 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1449643 | 0.96 | CHRNA7 (0.46) | CHRNA7KCNH2GFERGRIN1IMPDH2 | |
| SCHEMBL5441918 | 0.81 | CHRNA7 (0.40) | CHRNA7KCNH2GFERGRIN1IMPDH2 | |
| SCHEMBL2944661 | 0.80 | CHRNA7 (0.67) | CHRNA7KCNH2 | |
| SCHEMBL1023811 | 0.78 | GRM5 (0.41) | GRM5APP | |
| SCHEMBL1021484 | 0.77 | GRM5 (0.54) | CHRNA7GRM5 | |
| SCHEMBL3549772 | 0.77 | GFER (0.41) | CHRNA7KCNH2GFERGRIN1IMPDH2 | |
| SCHEMBL1397905 | 0.75 | CHRNA7 (0.71) | CHRNA7KCNH2CSNK1DMAPK11MAPK14 | |
| SCHEMBL1449960 | 0.75 | CHRNA7 (0.71) | CHRNA7KCNH2CSNK1DMAPK11MAPK14 | |
| SCHEMBL1450676 | 0.73 | GRM5 (0.44) | GRM5 | |
| SCHEMBL1449611 | 0.73 | GRM5 (0.55) | CHRNA7GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7662812-B2 | Diazabicyclic aryl derivatives and their use as chinolinergic ligands at nicotinic acetylcholine receptors | NEUROSEARCH A/S (DK) | 2010-02-16 | — | — | US | claimed |
| US-20080146582-A1 | disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances | NEUROSEARCH A/S (DK) | 2008-06-19 | — | — | US | claimed |
| US-7662812-B2 | Diazabicyclic aryl derivatives and their use as chinolinergic ligands at nicotinic acetylcholine receptors | NEUROSEARCH A/S (DK) | 2010-02-16 | — | — | US | disclosed |
| US-20080146582-A1 | disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances | NEUROSEARCH A/S (DK) | 2008-06-19 | — | — | US | disclosed |
| EP-1863819-A2 | DIAZABICYCLIC ARYL DERIVATIVES AND THEIR USE AS CHINOLINERGIC LIGANDS AT THE NICOTINIC ACETYLCHOLINE RECEPTORS | NEUROSEARCH A/S (DK) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006087306-A2 | DIAZABICYCLIC ARYL DERIVATIVES AND THEIR USE AS CHOLINERGIC LIGANDS AT THE NICOTINIC ACETYLCHOLINE RECEPTORS | NEUROSEARCH A/S (DK) | 2006-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146582-A1 | disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances | CHRNA6, CHRNA10, CHRNA2 | CHRNA7 7/4885KCNH2 1056/4885GFER 1880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.